{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:34:15Z","timestamp":1782401655789,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Lopinavir\/ritonavir, an anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drug, may be associated with the development of liver injury. In this paper, we reported an elderly female patient with drug-induced liver injury secondary to lopinavir\/ritonavir, which was evaluated for their causality using the updated Roussel Uclaf Causality Assessment Method (RUCAM) of 2016. She had a RUCAM score of 8 which was equivalent to a probable causality grading. Her clinical course was complicated by persistent hepatocyte secretion failure (PHSF), followed by septic shock and SARS-CoV-2 re-infection during her hospitalization. Her response to any medical intervention, including ursodeoxycholic acid, glutathione, methylprednisolone sodium succinate, rifampicin, artificial liver support, and endoscopic nasobiliary drainage (ENBD) was very poor, and her family members refused liver transplantation. Finally, she died. In summary, this case suggests the possibility that lopinavir\/ritonavir can cause DILI and even PHSF in our clinical practice.<\/jats:p>","DOI":"10.3389\/fmed.2025.1492002","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:09:16Z","timestamp":1738825756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Persistent hepatocyte secretory failure in lopinavir\/ritonavir related to drug-induced liver injury: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Yue","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai'e","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkai","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocheng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EAftSot. EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/medicines7100062","article-title":"Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: a comprehensive analysis","volume":"7","author":"Teschke","year":"2020","journal-title":"Medicines"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/15563650.2020.1842882","article-title":"Safety and effectiveness concerns of lopinavir\/ritonavir in COVID-19 affected patients: a retrospective series","volume":"59","author":"Lepage","year":"2021","journal-title":"Clin Toxicol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12985-021-01593-1","article-title":"Liver injury in COVID-19: clinical features and treatment management","volume":"18","author":"Yu","year":"2021","journal-title":"Virol J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/gutjnl-2020-321726","article-title":"Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19","volume":"70","author":"Yip","year":"2021","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.3390\/ijms23094828","article-title":"Liver injury in COVID-19 patients with drugs as causatives: a systematic review of 996 DILI cases published 2020\/2021 based on RUCAM as causality assessment method","volume":"23","author":"Teschke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/liv.12603","article-title":"Characterization and treatment of persistent hepatocellular secretory failure","volume":"35","author":"van Dijk","year":"2015","journal-title":"Liver Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1111\/jgh.15629","article-title":"Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure","volume":"36","author":"Shi","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1093\/cid\/ciad646","article-title":"The infectious diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing (December 2023)","volume":"78","author":"Hayden","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0195068","DOI":"10.1371\/journal.pone.0195068","article-title":"High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir\/ritonavir monotherapy: a randomized clinical trial","volume":"13","author":"Pasquau","year":"2018","journal-title":"PLoS ONE."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/jac\/dkn103","article-title":"Long-term (4 years) efficacy of lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"61","author":"Pulido","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.07.002","article-title":"Mechanisms of drug-induced liver injury","author":"Yuan","year":"2013","journal-title":"Clin Liver Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1019487","DOI":"10.3389\/fphar.2022.1019487","article-title":"Drug-induced liver injury in COVID-19 treatment: incidence, mechanisms and clinical management","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10557-020-07070-1","article-title":"Lopinavir-ritonavir in SARS-CoV-2 infection and drug-drug interactions with cardioactive medications","volume":"35","author":"Agarwal","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-021-97160-3","article-title":"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics","volume":"11","author":"Ambrus","year":"2021","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jps.1133","article-title":"Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line","volume":"90","author":"Perloff","year":"2001","journal-title":"J Pharm Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","article-title":"COVID-19: Abnormal liver function tests","volume":"73","author":"Cai","year":"2020","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.therap.2022.10.066","article-title":"Safety profile of the lopinavir\/ritonavir combination before and during the SARS-CoV-2 pandemic","volume":"78","author":"Lory","year":"2023","journal-title":"Therapie"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.2147\/DDDT.S259058","article-title":"Antiviral agent therapy optimization in special populations of COVID-19 patients","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"806249","DOI":"10.3389\/fphar.2021.806249","article-title":"Pharmacotherapies for drug-induced liver injury: a current literature review","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/biof.1136","article-title":"ATP-binding cassette transporters in liver","volume":"40","author":"Wlcek","year":"2014","journal-title":"Biofactors"},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-018-0475-8","article-title":"Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases","volume":"25","author":"Chen","year":"2018","journal-title":"J Biomed Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/pr.2015.247","article-title":"Inherited disorders of bilirubin clearance","volume":"79","author":"Memon","year":"2016","journal-title":"Pediatr Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1111\/liv.14662","article-title":"Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma","volume":"40","author":"de Vries","year":"2020","journal-title":"Liver Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1038\/s41598-021-82966-y","article-title":"ABCC6 deficiency promotes dyslipidemia and atherosclerosis","volume":"11","author":"Brampton","year":"2021","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1476-511X-13-118","article-title":"ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?","volume":"13","author":"Kuzaj","year":"2014","journal-title":"Lipids Health Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","article-title":"Liver disease associated with canalicular transport defects: current and future therapies","volume":"52","author":"Stapelbroek","year":"2010","journal-title":"J Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1492002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:09:21Z","timestamp":1738825761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1492002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1492002"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1492002","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"article-number":"1492002"}}